Japanese team creates artificial chromosome
03:11 p.m May 01, 1998 Eastern

WASHINGTON, May 1 (Reuters) - Japanese scientists said on Friday they had built an artificial chromosome, which might aid efforts to use gene therapy to treat diseases such as muscular dystrophy and cystic fibrosis.

Hiroshi Masumoto of Nagoya University in Japan and colleagues said they hoped their artificial gene might be used to deliver some form of gene therapy.

Every human cell contains 46 chromosomes. These, in turn carry the genes.

Everyone has some ``defective'' genes, but some defects have more serious effects than others. One inherited defect causes cystic fibrosis, for example -- a disease that causes the overproduction of mucus, leading to breathing and digestive problems and eventual death.

Sometimes replacing just a single gene would cure a disease, but getting the gene to ``take'' permanently has been impossible so far. Some scientists think that an extra miniature chromosome, carrying the therapeutic gene or genes, could do the trick.

Writing in the journal Nature Biotechnology, Masumoto's team said they had engineered a minichromosome and said it was stable in human cells. Also, importantly, it did not take on DNA from other chromosomes.

For a chromosome to work, it must have the end part, known as a telomere, and a middle part, known as a centromere. In previous experiments scientists have been able to throw the centromeres and telomeres into a cell and let it rearrange them into chromosomes.

But in the past the cell always threw in random bits of DNA, making it impossible to predict what the resulting chromosome would look like.

Masumoto's chromosomes do not have this problem. They are about one-tenth the size of a human chromosome.

The next step would be to try to add a therapeutic gene and see if it works. REUTERS

Copyright 1998 Reuters Limited. All rights reserved. Republication and redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Volver a Medios de Comunicación